The White House is pushing back in a New York Times report that it had the opportunity to buy more doses of Pfizer. Covid-19 vaccine This summer but declined, meaning Pfizer will not be able to offer more than the initial deal until June.
A senior administration official told reporters Monday that the New York Times story was false. The official said the Trump administration is in the midst of negotiations right now and cannot talk about it in public, but they feel “complete confidence” that the American who wants the vaccine will get one. The official said a preliminary agreement with Pfizer to buy 100 million doses was announced in July, and anyone seeking to sell additional doses at that time “would not get government money.”
Announcing the deal to buy 100 million doses of the vaccine in a July press release, Pfizer said the federal government had agreed to buy 100 million doses, adding that “the US government could also receive an additional 500 million doses.”
In a statement to CBS News, Pfizer said on Monday that the additional amount of over Rs 100 crore would have to be handled differently.
The company said the U.S. government had placed an initial order of 100 million doses for Pfizer-Bioentech’s COVID-19 vaccine, and Pfizer is ready to begin dosing soon after receiving emergency use authorization from the FDA. “Any additional amount in excess of 100 100 million is subject to separate and mutually acceptable agreement. The Company will not be able to comment on any ongoing confidential discussions with the US Government.”
Representatives from Pfizer and Moderna will not attend the White House Vaccine Summit this week.
The first vaccination is expected to reach vulnerable citizens and health care workers this month. The efficacy rate for Pfizer vaccine is over 90%.
Finn Gomez and Arden Farry contributed to this report.
.
